Clariant
Clariant AG is a Swiss multinational speciality chemicals company, formed in 1995 as a spin-off from Sandoz. The company is focused on four business areas: care chemicals (consumer and industrial); catalysis; natural resources (oil & mining, minerals); and plastics & coatings. Headquartered near Basel, Switzerland, the public company encompasses 110 operating companies in 53 countries. Major manufacturing sites are located in Europe, North America, South America, China, and India. In 2015, sales from continuing operations were 5.8 billion CHF.
Type | Public |
---|---|
SIX: CLN | |
Industry | Chemicals |
Founded | 1995 |
Headquarters | , |
Area served | Worldwide |
Key people | Conrad Keijzer (CEO) Stephan Lynen (CFO) Hans Bohnen (COO) Bernd Hoegemann (CTO) |
Products | Speciality chemicals |
Revenue | 6.623 billion CHF (2018)[1] |
356 million CHF (2018)[1] | |
Total assets | 7.981 billion CHF (2018)[2] |
Total equity | 2.970 billion CHF (2018)[2] |
Number of employees | 17,901 (2018)[3] |
Divisions | Care Chemicals Catalysis Natural Resources Plastics & Coatings |
Website | clariant |
European markets account for about one-third of sales, while Asia-Pacific, North America and Latin America account for about one-fifth each. Net income in 2015 was 227 million CHF, while EBITDA was 853 million CHF.[4] The company has sales of around US$6 billion. Headquarters are officially in Muttenz, but most central functions are officed in a dedicated corporate centre in nearby Pratteln, both near Basel, Switzerland. Clariant's four business areas, are: Plastics & Coatings (around 42% of sales), Care Chemicals (around 25% of sales), Natural Resources (around 21% of sales) and Catalysts (around 12% of sales).
Business history
The company started in 1995, as a spinoff (IPO) of the chemical operations of Sandoz, which then merged its pharmaceutical business with that of Ciba-Geigy to form Novartis. (Ciba-Geigy also went on to spin out its chemical operations, called Ciba Specialty Chemicals, which was later acquired by BASF.) In 1997, Clariant grew substantially, with the acquisition of the Hoechst speciality chemicals business.
In 2000, Clariant bought British Tar Products (BTP plc), in 2006 Clariant bought Ciba's Masterbatches division, and in 2011 Clariant acquired German speciality chemical company Süd-Chemie. In 2013, Clariant divested its textile chemicals, emulsions and paper specialities businesses to SK Capital. In 2014, Clariant divested its leather services to Stahl Holdings and its detergents & intermediates business to Weylchem of the International Chemical Investors Group. Clariant International Ltd partners with matchmycolor LLC, a colour know-how company and Konica Minolta Inc, a Japanese technology company to efficiently colour match the polyolefin products easier and faster.[5]
Merger of equals: HuntsmanClariant
In May 2017, Clariant and Huntsman Corporation announced that they would merge, as equals, forming HuntsmanClariant which would be the global leader in specialty chemical production - with the deal valued at $20 billion.[6][7] Clariant shareholders will own 52% of the new entity, with Huntsman shareholders owning the remaining 48% of shares.[8][9]
In October 2017, the merger between Clariant and Huntsman Corporation was halted due to concerns that a two-thirds shareholder approval, required by Swiss law, could not be reached. The all stock transaction would not have found support by White Tale Holdings, which continues to accumulate stocks while opposing the consolidation.[10]
On January 25, 2018, White Tale Holdings, which is a partnership between hedge fund Corvex Management LP and investment group 40 North, ended its hostility and sold 25% of its stake to SABIC despite previous assertions that it was a long term holder. Shares tumbled by as much as 11% on that news, wiping out approximately 1 billion Swiss francs ($1 billion) from the company's market value.[11]
Research & development
As of end-2015, some 1,100 of Clariant's some 17,000 employees were engaged in R&D, mainly at the company's 8 global R&D centers and its 50+ technical application centers. In 2015, the company spent CHF 204 million, or 3.5% of sales on R&D.
Sustainability
Clariant is a constituent of the Dow Jones Sustainability Index (DJSI) World and the DJSI Europe. It also is a constituent of the FTSE4Good Index.
Clariant Active Ingredients
In January 2017, Clariant opened a new business unit dedicated to active ingredients for the cosmetic industry. Based in Toulouse, within the Bioparc south of the Oncopole, this new unit is focused on expanding Clariant's portfolio of naturally sourced ingredients with its two strategic partners, BioSpectrum and Beraca.[12]
The new facility includes laboratories for product testing and skin biology studies, and dedicated R&D and marketing teams. At the end of 2017, Clariant Active Ingredients counted 17 employees.
See also
Notes
- "Clariant Integrated Report 2018". Clariant. Retrieved 11 March 2019.
- "Clariant Integrated Report 2018". Clariant. Retrieved 11 March 2019.
- "Clariant Integrated Report 2018". Clariant. Retrieved 11 March 2019.
- Clariant Corporate Presentation 2016
- "Clariant, matchmycolor, Konica to make colour matching easier, faster". WorldOfChemicals. Oct 24, 2016. Retrieved Oct 25, 2016.
- http://cen.acs.org/articles/95/web/2017/05/Clariant-Huntsman-join-20-billion.html
- https://www.wsj.com/articles/huntsman-clariant-near-deal-to-merge-1495403783
- http://www.clariant.com/en/Corporate/News/2017/05/Clariant-and-Huntsman-to-Combine-in-Merger-of-Equals
- https://www.ft.com/content/3a432c2c-3e76-11e7-9d56-25f963e998b2
- Huntsman and Clariant Halt Chemicals Merger, Citing Investor Revolt. The New York Times. (DealBook). Retrieved 27 October 2017.
- C. Hughes (Jan 2018). White Tale High-Tails It Bloomberg Gadfly. Retrieved 3 April 2018.
- "Clariant opens new facility dedicated to active ingredients". cosmeticsdesign-europe.com. Retrieved 2018-01-19.
References
- Anna Bálint: Clariant clareant. The beginnings of a specialty chemicals company, Campus Verlag, Frankfurt am Main/New York 2012, ISBN 978-3-593-39374-2.